RT Book, Section
A1 El-Haddad, Ghassan
A1 Hess, Søren
A1 Worsley, Daniel
A1 Alavi, Abass
A2 Grippi, Michael A.
A2 Elias, Jack A.
A2 Fishman, Jay A.
A2 Kotloff, Robert M.
A2 Pack, Allan I.
A2 Senior, Robert M.
A2 Siegel, Mark D.
SR Print(0)
ID 1122357557
T1 Physiologic and Metabolic Study of Pulmonary Disorders Using Conventional Imaging Techniques and Positron Emission Tomography
T2 Fishman's Pulmonary Diseases and Disorders, 5e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-179672-9
LK accessmedicine.mhmedical.com/content.aspx?aid=1122357557
RD 2023/03/22
AB Since  the  mid-1950s,  the  use  of  radiopharmaceuticals  has  made  it  possible  to  assess  a  variety  of  pulmonary  disorders.  In  1955,  133Xe  was  introduced  for  the  study  of  regional  pulmonary  ventilation.1  Shortly  thereafter,  it  became  possible  to  evaluate  regional  pulmonary  blood  flow  using  inhaled  carbon  dioxide  containing  radioactive  15O2  or  intravenous  injection  of  133Xe  dissolved  in  saline  solution.3  In  1964,  intravenous  injection  of  131I-macroaggregated  albumin  made  it  feasible  to  obtain  perfusion  scans  of  the  lungs.4  Although  these  techniques  rapidly  gained  wide  acceptance  as  tests  of  regional  abnormalities  in  ventilation  and  pulmonary  blood  flow,  the  main  practical  application  has  been  in  the  diagnostic  evaluation  of  patients  with  suspected  pulmonary  embolism  (PE).  Increasingly,  the  role  of  nuclear  medicine  in  respiratory  medicine  has  been  expanded  to  include  disorders  such  as  preoperative  assessment  of  lung  function,  inflammatory  lung  disease,  and  lung  cancer.  The  more  widespread  availability  of  positron  emission  tomography  (PET)  and  integrated  PET/CT  (computed  tomography)  has  provided  powerful  tools  to  aid  in  the  diagnosis,  staging,  and  management  of  patients  with  lung  cancer.